Oct 12, 2022 8:00am EDT Inhibikase Therapeutics to Present at the Cambridge Healthtech Institute's Inaugural Neurodegeneration Targets Conference
Sep 21, 2022 4:05pm EDT Inhibikase Therapeutics to Present at the Grand Challenges in Parkinson's Disease Conference
Sep 15, 2022 8:00am EDT Inhibikase Therapeutics to Present Data from Phase 1/1b study of IkT-148009 at the Movement Disorders Society Congress
Sep 08, 2022 8:30am EDT Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders
Aug 26, 2022 8:00am EDT Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia
Aug 23, 2022 8:00am EDT Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2a '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease
Aug 12, 2022 4:55pm EDT Inhibikase Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity
Aug 08, 2022 8:30am EDT Inhibikase Therapeutics to Report Second Quarter 2022 Financial Results on August 12, 2022
Jun 13, 2022 8:00am EDT Inhibikase Therapeutics Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review